Antiretroviral therapy in AIDS patients with tuberculosis

AIDS Reviews

Volumn 8, Issue 3, 2006, Pages 115-124

  Moreno, Santiago ^a   Hernández, Beatriz ^a   Dronda, Fernando ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

HIV; Nonnucleoside reverse transcriptase inhibitors; Protease inhibitors; Rifabutin; Rifampin; Tuberculosis

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; PERIPHERAL NEUROPATHY; REVIEW; SKIN MANIFESTATION; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; HUMANS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMYCINS; TUBERCULOSIS;

EID: 33750378430     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Lawn S, Badri M, Word R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South Africa cohort. AIDS 2005;19:2109-16.
2. The Antiretroviral Therapy Cohort Collaboration. incidence of TB among HIV-infected patients receiving HAART in Europe and North America. Clin Infect Dis 2005;41:1772-82.
3. Centers for Disease Control. Prevention and treatment of TB among patients infected with HIV: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998;47:1-51.
4. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of TB among HIV-infected patients taking PI or NNRTI. MMWR Morb Mortal Wkly Rep 2000;49:185-9.
5. Barnes P, Lakey D, Burman W. Tuberculosis in patients with HIV infection. Infect Dis Clin North Am 2002;16:107-26.
6. Pedral-Sampaio D, Netto E, Brites C, et al. Treating TB in AIDS patients: when to start and how long to keep giving drugs? AIDS 2002;6:1845.
7. Dean G, Edwards S, Ives N, et al. Treatment of TB in HIV-infected persons in the era of HAART. AIDS 2002;16:75-83.
8. Narita M, Ashkin D, Hollender E, Pitchenik A. Paradoxical worsening of TB following ARV therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61.
9. Navas E, Martín-Dávila P, Moreno L, et al. Paradoxical reactions of TB in AIDS patients treated with HAART. Arch Intern Med 2002; 162:97-9.
10. American Thoracic Society. Treatment of TB and TB infection in adults and children. Am J Respir Crit Care Med 1994;146: 1623-33.
11. Chaulk C, Moore-Rice K, Pizzo R, Chaisson R. Eleven years of community based directly observed therapy for TB. JAMA 1995; 274:945-51.
12. Burman W, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of HIV-related TB. Clin Infect Dis 1999;28:419-30.
13. Pozniak A, Miller R, Ormerod L. The treatment of TB in HIV-infected persons. AIDS 1999;13:435-45.
14. Shao H, Crump J, Ramadhani H, et al. A randomized trial of early vs. delayed fixed-dose combination zidovudine/lamivudine/abacavir in patients coinfected with HIV and TB: early findings of the TB and HIV immune reconstitution trial. 13th CROI, Denver, USA, February 5-8, 2006 [abstract 796].
15. Moreno S, Poclzamczer D, Blázquez R, et al. Treatment of TB in HIV-infected patients: Safety and ARV efficacy of the concomitant use of ritonavir and rifampin. AIDS 2001;15:1185-7.
16. Department of Health and Human Services. Guidelines for the use of ARV agents in HIV-1 infected adults and adolescents. Available at http://AIDSinfo.nih.gov
17. Justesen U, Andersen A, Klitgaard N, Brosen K, Gerstoft J, Pedersen C. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis 2004;38:426-9.
18. Ribera E, Azuaje C, Lopez RM, et al. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard TB therapy (TBQD Study). J Acquir Immune Defic Syndr 2005;40:317-23.
19. La Porte C, Colbers E, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir/ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004;48:1553-60.
20. Hamzeh F, Benson C, Gerber J, et al. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003;73:159-69.
21. Spradling P, Drociuk D, McLaughlin S, et al. Drug-drug interactions in inmates treated for HIV and Mycobacterium tuberculosis infection or disease: an institutional TB outbreak. Clin Infect Dis 2002;35:1106-12.
22. Palma E, Stambaugh J, Akinlobi O, Narita M, Hollender E, Ashkin D. The use of rifabutin with NFV-containing HAART in 48 HIV-infected TB patients. 8th CROI, Chicago, USA, February 4-8, 2001 [abstract 741].
23. Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron D. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with HIV. Clin Pharmacol Ther 2001;70:149-58.
24. Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIV-infected patients. 36th ICAAC, New Orleans, USA, September 15-18, 1996 [abstract A-27].
25. Chen Y, Ford SL, Shelton M, et al. Pharmacokinetic interaction between rifabutin and fosamprenavir/ritonavir in healthy subjects. 45th ICAAC, Washington DC, USA, December 16-19, 2005 [Abstract A-1199].
26. Bonora S, Boffito M, D'Avolio A, et al. Pharmacokinetics of rifabutin coadministered with lopinavir/ritonavir in HIV patients affected by TB. 2nd IAS Conference on HIV pathogenesis and treatment, Paris, France, July 13-16, 2003 [abstract 863].
27. Agarwala S, Mummaneni V, Randall D, Geraldes M, Stoltz R, OMara E. Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects. 9th CROI, Seattle, USA, February 24-28, 2002 [abstract 445].
28. Van Heeswijk R, Sabo J, Macgregor T, et al. The pharmacokinetic interaction between single-dose rifabutin and steady-state tipranavir/ ritonavir 500/200 mg bid in healthy volunteers. 44th ICAAC, Washington DC, USA, October 30-November 2, 2004 [abstract A-456].
29. Robinson P, Lamson M, Gigliotti M, et al. Pharmacokinetic interaction between nevirapine and rifampicin. 12th World AIDS Conference. Geneva, Switzerland, June 28-July 3, 1998 [abstract 60623].
30. Havlir D, Cheeseman S, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with HIV infection. J Infect Dis 1995;171:537-45.
31. Autar RS, Wit F, Sankot J, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and TB. Antivir Ther 2005;10:937-43.
32. Dean G, Back D, de Ruiter A. Impact of TB therapy on nevirapine trough plasma concentrations. AIDS 1999;13:2489-90.
33. Ribera E, Pou L, Lopez R, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with TB. J Acquir Immune Defic Syndr 2001;28:450-3.
34. Oliva J, Moreno S, Sanz J, et al. Coadministraton of rifampin and nevirapine in HIV-infected patients with TB. AIDS 2003;17:637-8.
35. Benedek I, Joshi A, Fiske W, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers. 12th World AIDS Conference. Geneva, Switzerland, June 28-Juiy 3, 1998 [abstract 42280].
36. López Cortés L, Ruiz Valdera R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampin in HIV-infected patients with TB. Clin Pharmacokinet 2002;41:681-90.
37. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with TB receiving HAART and rifampicin. AIDS 2005;19:1481-6.
38. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and TB: one size does not fit all. AIDS 2005;19:1541-6.
39. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and ARV effectiveness of concomitant use of rifampicin and efavirenz for ARV-naive patients in India who are coinfected with TB and HIV-1. J Acquir Immune Defic Syndr 2004;37:1166-9.
40. Pedral-Sampaio D, Alves C, Netto E, Brites C, Oliveira AS, Baclaro R. Efficacy and safety of efavirenz in HIV patients on rifampin for TB. Brazil J Infect Dis 2004;8:211-6.
41. Manosuthi W, Kiertiburanakul S, Ruxrungtham K, et al. Efavirenz 600 mg/ day versus efavirenz 800 mg/day in HIV-infected patients with TB receiving rifampicin: 48-week results. AIDS 2006;20:131-2.
42. Hollander E, Stambaugh J, Ashkin D, Akinlabi O, Narita M. The concomitant use of rifabutin and efavirenz in HIV/TB coinfected patients. 10th CROI, Boston, USA, February 10-14, 2003 [abstract 785].
43. Weiner M, Benator D, Peloquin C, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and TB. Clin Infect Dis 2005;41:1343-9.
44. Burman W, Benator D, Vernon A, et al. Use of antiretroviral therapy during treatment of active TB with a rifabutin-based regimen. 10th CROI, Boston, USA, February 10-14, 2003 [abstract 136].
45. Treatment of Tuberculosis. American Thoracic Society, CDC and Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2003;52:1-77.
46. Recomendaciones de GESIDA/Plan Nacional Sobre el Sida respecto al tratamiento antirretroviral an pacientes adultos infectados por VIH (diciembre 2005). http://www.msc.es/ciudadanos/enfLesiones/ enfTransmisibles/docs/RecomendacionesTARGESIDA_PN_diciembre2005.pdf
47. De Jong B, Israelski D, Corbett E, Small P. Clinical management of TB in the context of HIV infection. Annu Rev Mad 2004;55: 283-301.
48. Moreno S, Oliva J, Navas E, et al. Optimal timing of administration of ART in AIDS patients with TB. 12th CROI, Boston, USA, February 22-25, 2005 [abstract 890].